B. Metzler seel. Sohn & Co. AG Grows Stock Position in ResMed Inc. $RMD

B. Metzler seel. Sohn & Co. AG increased its holdings in shares of ResMed Inc. (NYSE:RMD) by 28.2% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 8,758 shares of the medical equipment provider’s stock after purchasing an additional 1,928 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in ResMed were worth $1,960,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in ResMed by 1.8% during the first quarter. Vanguard Group Inc. now owns 18,493,702 shares of the medical equipment provider’s stock worth $4,139,815,000 after buying an additional 320,240 shares during the period. Northern Trust Corp increased its stake in ResMed by 2.5% during the first quarter. Northern Trust Corp now owns 1,744,541 shares of the medical equipment provider’s stock worth $390,516,000 after acquiring an additional 41,951 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in ResMed by 4.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 998,128 shares of the medical equipment provider’s stock worth $223,431,000 after acquiring an additional 41,108 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in ResMed by 28.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 954,612 shares of the medical equipment provider’s stock worth $218,310,000 after acquiring an additional 212,201 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in ResMed by 6.9% during the first quarter. Dimensional Fund Advisors LP now owns 793,760 shares of the medical equipment provider’s stock worth $177,652,000 after acquiring an additional 51,348 shares during the last quarter. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ResMed

In other ResMed news, Director John Hernandez sold 2,575 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $287.10, for a total transaction of $739,282.50. Following the completion of the sale, the director owned 4,045 shares in the company, valued at $1,161,319.50. This trade represents a 38.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peter C. Farrell sold 945 shares of the firm’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $255.49, for a total value of $241,438.05. Following the sale, the director owned 68,273 shares of the company’s stock, valued at approximately $17,443,068.77. This trade represents a 1.37% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,638 shares of company stock worth $7,311,177 in the last 90 days. 0.71% of the stock is owned by corporate insiders.

ResMed Price Performance

RMD stock opened at $274.78 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.53 and a current ratio of 3.44. ResMed Inc. has a 1 year low of $199.92 and a 1 year high of $293.81. The firm has a market cap of $40.23 billion, a P/E ratio of 28.89, a price-to-earnings-growth ratio of 1.84 and a beta of 0.77. The stock has a 50-day simple moving average of $270.83 and a 200-day simple moving average of $245.98.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, July 31st. The medical equipment provider reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.47 by $0.08. ResMed had a return on equity of 25.62% and a net margin of 27.22%.The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.33 billion. During the same quarter last year, the firm earned $2.08 EPS. ResMed’s quarterly revenue was up 10.2% on a year-over-year basis. On average, equities analysts predict that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 18th. Shareholders of record on Thursday, August 14th will be paid a dividend of $0.60 per share. This is a boost from ResMed’s previous quarterly dividend of $0.53. The ex-dividend date is Thursday, August 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. ResMed’s payout ratio is 25.24%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. KeyCorp upped their price target on ResMed from $274.00 to $298.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. UBS Group upped their price target on ResMed from $285.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Mizuho upped their price target on ResMed from $270.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, August 1st. Wall Street Zen lowered ResMed from a “buy” rating to a “hold” rating in a research note on Sunday, August 10th. Finally, Morgan Stanley set a $286.00 price target on ResMed and gave the stock an “overweight” rating in a research note on Tuesday, May 20th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, ResMed has a consensus rating of “Moderate Buy” and a consensus target price of $274.83.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.